Matches in SemOpenAlex for { <https://semopenalex.org/work/W3177122952> ?p ?o ?g. }
- W3177122952 endingPage "515" @default.
- W3177122952 startingPage "503" @default.
- W3177122952 abstract "Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown.In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks.The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide.In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.)." @default.
- W3177122952 created "2021-07-05" @default.
- W3177122952 creator A5013568217 @default.
- W3177122952 creator A5014528965 @default.
- W3177122952 creator A5040651874 @default.
- W3177122952 creator A5045489578 @default.
- W3177122952 creator A5057457335 @default.
- W3177122952 creator A5058864022 @default.
- W3177122952 creator A5072715491 @default.
- W3177122952 creator A5084593004 @default.
- W3177122952 creator A5086072427 @default.
- W3177122952 date "2021-08-05" @default.
- W3177122952 modified "2023-10-17" @default.
- W3177122952 title "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes" @default.
- W3177122952 cites W2008082500 @default.
- W3177122952 cites W224688689 @default.
- W3177122952 cites W2414002317 @default.
- W3177122952 cites W2519510391 @default.
- W3177122952 cites W2572398654 @default.
- W3177122952 cites W2602700371 @default.
- W3177122952 cites W2604469807 @default.
- W3177122952 cites W2774157762 @default.
- W3177122952 cites W2787255324 @default.
- W3177122952 cites W2801715295 @default.
- W3177122952 cites W2894993577 @default.
- W3177122952 cites W2895135221 @default.
- W3177122952 cites W2895666357 @default.
- W3177122952 cites W2918407168 @default.
- W3177122952 cites W2973758715 @default.
- W3177122952 cites W2974008202 @default.
- W3177122952 cites W2978840913 @default.
- W3177122952 cites W3004172664 @default.
- W3177122952 cites W3011482816 @default.
- W3177122952 cites W3127462604 @default.
- W3177122952 cites W3133746780 @default.
- W3177122952 cites W4237332786 @default.
- W3177122952 cites W4250740255 @default.
- W3177122952 doi "https://doi.org/10.1056/nejmoa2107519" @default.
- W3177122952 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34170647" @default.
- W3177122952 hasPublicationYear "2021" @default.
- W3177122952 type Work @default.
- W3177122952 sameAs 3177122952 @default.
- W3177122952 citedByCount "500" @default.
- W3177122952 countsByYear W31771229522021 @default.
- W3177122952 countsByYear W31771229522022 @default.
- W3177122952 countsByYear W31771229522023 @default.
- W3177122952 crossrefType "journal-article" @default.
- W3177122952 hasAuthorship W3177122952A5013568217 @default.
- W3177122952 hasAuthorship W3177122952A5014528965 @default.
- W3177122952 hasAuthorship W3177122952A5040651874 @default.
- W3177122952 hasAuthorship W3177122952A5045489578 @default.
- W3177122952 hasAuthorship W3177122952A5057457335 @default.
- W3177122952 hasAuthorship W3177122952A5058864022 @default.
- W3177122952 hasAuthorship W3177122952A5072715491 @default.
- W3177122952 hasAuthorship W3177122952A5084593004 @default.
- W3177122952 hasAuthorship W3177122952A5086072427 @default.
- W3177122952 hasBestOaLocation W31771229521 @default.
- W3177122952 hasConcept C126322002 @default.
- W3177122952 hasConcept C134018914 @default.
- W3177122952 hasConcept C170493617 @default.
- W3177122952 hasConcept C185280430 @default.
- W3177122952 hasConcept C2777180221 @default.
- W3177122952 hasConcept C2777538456 @default.
- W3177122952 hasConcept C2778917026 @default.
- W3177122952 hasConcept C2778938600 @default.
- W3177122952 hasConcept C2781308992 @default.
- W3177122952 hasConcept C2909862629 @default.
- W3177122952 hasConcept C44249647 @default.
- W3177122952 hasConcept C555293320 @default.
- W3177122952 hasConcept C71924100 @default.
- W3177122952 hasConcept C90924648 @default.
- W3177122952 hasConceptScore W3177122952C126322002 @default.
- W3177122952 hasConceptScore W3177122952C134018914 @default.
- W3177122952 hasConceptScore W3177122952C170493617 @default.
- W3177122952 hasConceptScore W3177122952C185280430 @default.
- W3177122952 hasConceptScore W3177122952C2777180221 @default.
- W3177122952 hasConceptScore W3177122952C2777538456 @default.
- W3177122952 hasConceptScore W3177122952C2778917026 @default.
- W3177122952 hasConceptScore W3177122952C2778938600 @default.
- W3177122952 hasConceptScore W3177122952C2781308992 @default.
- W3177122952 hasConceptScore W3177122952C2909862629 @default.
- W3177122952 hasConceptScore W3177122952C44249647 @default.
- W3177122952 hasConceptScore W3177122952C555293320 @default.
- W3177122952 hasConceptScore W3177122952C71924100 @default.
- W3177122952 hasConceptScore W3177122952C90924648 @default.
- W3177122952 hasFunder F4320307758 @default.
- W3177122952 hasIssue "6" @default.
- W3177122952 hasLocation W31771229521 @default.
- W3177122952 hasLocation W31771229522 @default.
- W3177122952 hasLocation W31771229523 @default.
- W3177122952 hasOpenAccess W3177122952 @default.
- W3177122952 hasPrimaryLocation W31771229521 @default.
- W3177122952 hasRelatedWork W1877152454 @default.
- W3177122952 hasRelatedWork W2027913950 @default.
- W3177122952 hasRelatedWork W2028293475 @default.
- W3177122952 hasRelatedWork W2050423574 @default.
- W3177122952 hasRelatedWork W2058205365 @default.
- W3177122952 hasRelatedWork W2070611629 @default.